Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Thermo Fisher Scientific Launches MAS Omni Infectious | Contract Pharma

What are you searching for?

Sign in
Breaking News

Thermo Fisher Scientific Launches MAS Omni Infectious

Quality control sets for monitoring serological assays for analytes such as HIV 1&2, Hepatitis B & C virus, Syphilis and HTLV I/II

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Thermo Fisher Scientific announced the availability of its MAS Omni Infectious Disease quality control sets for monitoring serological assays for analytes such as HIV 1&2, Hepatitis B & C virus, Syphilis and HTLV I/II.

Serology testing for infectious diseases continues to be on the rise and newer instrument platforms are offering serology markers with improved sensitivity than previously available. In addition, there is continued progression with infectious disease screening protocols requiring serology testing for diagnosis, monitoring and treatment of infectious agents.

The Thermo Scientific MAS Omni Infectious positive and negative quality controls are third-party, independent external controls used to assess the performance of serological assays for infectious diseases. The new control set supports assays for HIV, Hepatitis C, Hepatitis B, HTLV and Syphilis. MAS Quality Controls users can efficiently monitor assay performance, streamline operations and potentially reduce costs without sacrificing quality or throughput.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters